Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859. 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image

This Company Is Betting On Innovation To Make A Splash In Multiple Healthcare Markets And It Hit Multiple Milestones This Year

Benzinga

By James Blacker, Benzinga Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making visible strides with its diverse portfolio of innovative medical devices and diagnostic solutions designed to address unmet clinical needs. With its flagship product the Venowave VW5, a product designed to enhance blood circulation, Therma Bright is aiming to capitalize on a deep vein thrombosis (DVT) treatment market expected to grow to $1.62 billion by 2032. Beyond this, the company’s ambitions expand to developing cutting-edge technology to tackle a variety of health challenges, from respiratory disease management to pain relief. Over 2024, Therma Bright secured multiple milestones that indicate the growing attention it is receiving. The Venowave: A Potential Game-Changer in DVT Prevention The Venowave VW5 is an FDA-approved circulation booster designed to improve circulation in the lower extremities. Worn on the calf, the lightweight device stimulates blood flow with wave-like motions that massage the leg, forcing blood from the feet and legs back to the heart and preventing the formation of blood clots. This is particularly effective in cases of DVT, a condition that affects up to 900,000 people in the U.S. and that, if left untreated, can lead to serious complications such as a pulmonary embolism. Beyond just DVT, the Venowave has a range of other healthcare applications, such as managing symptoms of post-thrombotic syndrome, preventing primary thrombosis and treating lymphedema. In an encouraging sign for the product, Therma Bright announced on 27 August that it has secured a nationwide U.S. distribution partner for Venowave. Subject to the success of an initial sales program, this unnamed partner has committed to acquiring inventory worth $2.38 million. Also in August, Therma Bright received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS). This crucial designation increases the product’s credibility and could be a key catalyst to help propel Therma Bright to a leadership position in the DVT treatment market. Preva®: Clot Retrieval For Stroke Treatment The global coronary stents market was estimated to be $8.82 billion in 2022 and is expected to grow at a compound annual growth rate of 7.82% to reach $16.14 billion by 2030. Positioning itself to take a share of this growing market, Therma Bright has added to its diverse portfolio of late-stage products by investing in Inretio, the developer of the Preva® clot-retrieval device. The company hopes this device will revolutionize ischemic stroke treatment by improving effectiveness and preventing complications during thrombectomy procedures. The technology, which recently completed its third successful human trial, promises to offer a new approach to clot retrieving that reduces the need for repeated maneuvers and minimizes the risk of embolization. With more than 690,000 ischemic stroke patients in the U.S. each year, this potentially game-changing device could be the breakthrough in clot retrieval needed to significantly improve their lives. Another Growth Opportunity In The COPD Market Another of Therma Bright’s ventures that may hold promise is its stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). Unlike traditional oral therapies, InStatin targets the lungs directly, and the company hopes to provide a more effective treatment option for a range of respiratory conditions that affect millions of people worldwide. With the COPD market alone estimated to be worth over $16 billion annually, Therma Bright could stand to benefit from InStatin’s growth trajectory as its therapies advance through pre-clinical trials. Therma Bright previously owned a 17% stake in InStatin, but this percentage is set to increase as the company recently announced that it has expanded its investment. More In The Pipeline Therma Bright’s innovation pipeline doesn’t stop there. Other products in development include a Digital Cough Test app developed in partnership with AI4LYF. The app uses AI to monitor respiratory diseases based on the sound of a person’s cough. The cough data is reviewed by a doctor via an AI dashboard who can use the information to then treat the patient. Other products in Therma Bright’s portfolio include the Benepod™ Hot & Cold Contrast Therapy Device for Pain Relief, the AcuVid™ COVID-19 Rapid Antigen Test Solution, InterceptCS™ for at-home cold sore prevention and the TherOZap™ thermal therapy for insect bite relief. Why You May Want To Keep An Eye On Therma Bright With the global DVT market expected to reach $1.5 billion by 2032 and other innovations like the Preva® device and inhaled statins addressing multi-billion-dollar markets, Therma Bright could be well-positioned to capture a significant market share in multiple growing markets. Investors may want to keep an eye on this small company with a current market cap of about $20 million whose stock has rallied over 350% this year (as of Sep. 5) as it expands its presence in industries worth billions of dollars. Featured photo by Narupon Promvichai from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:58 AM Eastern Daylight Time

Image

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. Joonhyuk brings over 25 years of extensive experience in the pharmaceutical industry, underpinned by his academic background in electrical and computer engineering from Rutgers University in New Jersey. His prominent career is distinguished by a strong track record in developing clinical trial software, navigating the US FDA’s drug and medical device approval processes, managing clinical trials, and leading business development success. Prior to joining Syntekabio, Joonhyuk served as CEO of Target Health, a US-based contract research organization (CRO). There, he played a pivotal role in clinical operations and drove business development, spearheading sales and marketing teams while overseeing the development and maintenance of validated software solutions for clinical trials and data management for over two decades. Syntekabio anticipates that Joonhyuk, with his deep understanding of the drug development process from AI-driven drug discovery and clinical trials to drug approvals as well as business development, coupled with his extensive knowledge of the US market, will significantly enhance the company’s strategic partnership and revenue-generating initiatives. “I am honored to join Syntekabio at such a pivotal moment in the company’s journey,” said Joonhyuk Choi, newly appointed Head of US Operations. “I am committed to leveraging strategies tailored to the unique dynamics of the US pharma and biotech market to enhance the global reach and impact of Syntekabio’s AI drug discovery platform.” Jongsun Jung, PhD, CEO of Syntekabio, remarked, “With Joonhyuk’s appointment, Syntekabio is now strategically positioned to collaborate with potential partners across the entire drug development spectrum, from AI-driven candidate screening to clinical trials. His extensive expertise and experience in the US market will be crucial in driving our global expansion and enhancing our competitiveness, positioning us for achieving sustained business success.” About SyntekabioSyntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries – US & Europe - Laurie Doyle MC Services AG +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 10, 2024 08:00 AM Eastern Daylight Time

No More Wisdom Teeth Horror Stories? TriAgenics' Alternative To Painful Wisdom Teeth Removal

Benzinga

By Mangeet Kaur Bouns, Benzinga For countless people, the prospect of wisdom teeth removal stirs a deep sense of dread. While many undergo the procedure without incident, the reality is that this “routine” surgery is fraught with risks that can turn a simple operation into a painful and protracted ordeal. Complications are not just possible – they’re common. Dry sockets, for example, occur when the blood clot that forms after extraction becomes dislodged, exposing the underlying bone and nerves. The pain from a dry socket can be intense – often radiating to the ear – and it can take weeks for full recovery. Nearly 30% of patients experience bleeding, which, if not properly managed, can lead to further complications. Nerve damage, though less frequent, can result in permanent changes in sensation, affecting the lower lip, chin and gums. Even more concerning are the cases where wisdom teeth removal leads to life-threatening outcomes. The tragic story of 17-year-old Jenny Olenick, who suffered fatal brain damage due to oxygen deprivation while under anesthesia for a wisdom tooth extraction, serves as a somber reminder that no surgery is ever truly routine. Despite the best efforts of medical professionals, Jenny’s surgery ended in tragedy, a stark example of the potential dangers inherent in this common procedure. Complications Beyond The Expected: A Risky Rite Of Passage While stories like Jenny Olenick’s are rare, they highlight the unpredictable nature of wisdom teeth removal. What starts as a straightforward procedure can quickly spiral into a series of complications that demand additional medical intervention, prolong recovery and increase costs. For many patients, the aftermath of surgery is marked by a litany of issues: swelling, pain and difficulty opening the mouth are common, sometimes persisting for weeks. Trismus, a condition characterized by painful jaw movement, is particularly prevalent among younger patients, especially those between the ages of 17 and 25. This condition can make it challenging to perform everyday activities such as eating and speaking, further complicating the recovery process. Infections are another frequent concern, often manifesting as persistent discomfort, swelling and, in severe cases, fever or yellow discharge from the extraction site. If left untreated, these infections can lead to more serious complications, requiring antibiotics or even additional surgery. Sinus complications can occur in cases where the upper wisdom teeth are involved, adding another layer of risk. If the tooth roots are close to the sinus cavity, the removal can create an opening between the tooth socket and the sinus. This condition, known as sinus communication, can cause ongoing discomfort and complicate the healing process. Anesthesia reactions, although rare, pose their own risks, ranging from mild nausea to severe allergic reactions. In extreme cases, these reactions can be life-threatening. Such incidents, while uncommon, underscore the need for thorough preparation and careful monitoring during any surgical procedure. Given these risks, there is a clear unmet need for a safer, more reliable alternative to traditional wisdom teeth removal practices. Triagenics And Zero3 TBA: A Game-Changing Solution? Enter TriAgenics, a company potentially on the cusp of revolutionizing dental care with its innovative Zero3 Tooth Bud Ablation (TBA) technology. This procedure promises a potential end to the painful and often risky process of wisdom teeth removal by preventing wisdom teeth from forming in the first place. Zero3 TBA treatment is designed for children ages 6 to 12, a time when the early signs of wisdom teeth can be detected. The procedure is minimally invasive and highly precise, targeting and neutralizing the developing tooth bud tissue before it can grow into problematic third molars. TriAgenics reports that the entire process takes only 60 to 90 seconds per tooth bud, with the full treatment, which involves four tooth buds, completed in about 30 minutes. The company says that what makes Zero3 TBA particularly compelling is the simplicity and effectiveness of the procedure. Traditional wisdom teeth extraction involves cutting into the gums and bone to remove the teeth, which often leads to significant pain and a lengthy recovery period. Zero3 TBA is quick, minimally invasive and comes with minimal recovery time. The procedure’s targeted approach means that the risks of complications such as dry socket, nerve damage and infection are significantly reduced if not entirely eliminated, says TriAgenics. Disrupting A Multi-Billion Dollar Market The potential market for TriAgenics’ Zero3 TBA technology is large. With approximately 85% of all wisdom teeth eventually requiring removal, the demand for a preventative solution is clear. The company estimates that its Zero3 TBA product could tap into a total addressable market of more than $2.5 billion annually. TriAgenics is already on its way to capitalizing on this opportunity. The company has completed extensive research and development, achieving a 100% success rate in animal trials in preventing wisdom tooth formation. This success has paved the way for the next critical step: obtaining FDA clearance. If approved, TriAgenics plans to begin commercializing Zero3 TBA in 2025, with licensed dentists treating patients. The process will involve dentists sending X-rays and prescriptions to TriAgenics, which will then produce custom 3TBA guides. These guides, designed specifically for each patient, will be sold to dentists at an estimated $350 per tooth bud treated. The company has already raised over $11.5 million in capital, a testament to the investor interest in its technology. Furthermore, TriAgenics has established a robust intellectual property portfolio, securing 32 U.S. and international patents, expanding patent coverage in Australia, Canada, Europe and Mexico. This IP position, combined with growing interest from oral surgeons and pediatric dental specialists, potentially positions TriAgenics as a frontrunner in the future of dental care. Potential To Transform Dental Care As TriAgenics advances toward FDA clearance and market entry, the company could be poised to disrupt the traditional approach to wisdom teeth management. Zero3 TBA offers a solution that could spare tens of millions from the pain, risks and costs associated with wisdom teeth removal. By preventing the formation of wisdom teeth, TriAgenics is not just offering a new product; it’s proposing a paradigm shift in how dental care is approached. “Dental practitioners have expressed tremendous excitement about the potential to eliminate all complications normally associated with wisdom teeth removal,” said Dr. Leigh Colby, TriAgenics CEO. “We believe this will be the industry standard of care by 2030.” The implications of Zero3 TBA extend beyond just a single procedure. If successful, the company believes this technology could set a new standard in preventative dental care, reducing the need for invasive surgeries and the associated complications that may come with them. This means less pain, fewer risks and significant cost savings for patients. For the dental industry, it could represent a major leap forward in how care is delivered. To explore how TriAgenics is shaping the future of wisdom teeth management, check out TriAgenics on StartEngine. Featured photo by S&B Vonlanthen on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 09, 2024 08:35 AM Eastern Daylight Time

Image

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF): Major Approvals Make TBRIF A Stock To Watch

TBRIF

The medical device sector is experiencing rapid growth, driven by technological advancements and rising global healthcare needs. According to Statista, the global market is set to expand at an annual rate of 5.71%, reaching $673.10 billion by 2029. In 2024 alone, the United States is expected to generate $179.80 billion in medical device revenues, underscoring the sector’s substantial potential. In this burgeoning market, Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) stands out as an emerging leader. The company has made notable progress in diagnostics and health-tech solutions, with recent milestones such as the approval of reimbursement for its Venowave VW5 device. These developments highlight Therma Bright’s strong growth potential and its ability to open new revenue streams in the healthcare and medical technology sectors. Reimbursement Approval: A Game-Changer for Revenue On August 19, 2024, Therma Bright announced a landmark achievement with the U.S. Centers for Medicare and Medicaid Services (CMS) granting permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 to its Venowave VW5 device. This approval signifies a major breakthrough, as it not only provides a specific reimbursement code but also sets a precedent for the device's integration into the U.S. healthcare system. Rob Fia, CEO of Therma Bright, expressed his enthusiasm about the development: "We're pleased that the Centers for Medicare and Medicaid have approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device." This approval ensures that Venowave VW5 will be reimbursed for up to $1,199 per device or $78.05 per month for rental, totaling up to $819.55 over 13 months. The device addresses critical circulatory issues, including deep vein thrombosis (DVT), a condition affecting over 900,000 U.S. citizens annually. The reimbursement approval opens a major revenue channel for Therma Bright. Market research projects that the global market for DVT-related treatments will reach $1.5 billion by 2032. With the Venowave VW5 device being the first of its kind to receive a permanent HCPCS code, Therma Bright is poised to capture a significant share of this expanding market. Strategic Investments and Expanding Market Reach In addition to the reimbursement milestone, Therma Bright has been actively expanding its footprint through strategic investments and partnerships. On August 22, 2024, the company announced the securing of a nationwide U.S. distribution partner for the Venowave VW5. This partner will launch an initial sales program to assess Medicare/Medicaid reimbursement timelines and billing procedures, with a commitment to acquire inventory valued at up to $2.38 million post-program success. The partnership is a testament to the confidence in Venowave’s market readiness and the anticipated success of the reimbursement process. Rob Fia highlighted the significance of this deal: "We are thrilled to welcome our nationwide distribution partner to our team... We expect the program to be successful, leading to a significant increase in Venowave orders on a monthly basis and accelerating our revenue growth." Innovative Technological Advancements Therma Bright’s innovative approach extends beyond Venowave. On August 16, 2024, the company revealed that its AI-powered Digital Cough Technology (DCT) is under consideration for a clinical trial involving a new chronic cough drug. This AI-driven platform aims to enhance data collection and clinical decision-making, showcasing Therma Bright’s commitment to advancing healthcare technology. Additionally, Therma Bright continues to make strategic investments in cutting-edge solutions. On August 6, 2024, the company increased its investment in InStatin, a firm developing an inhaled statin for chronic lung conditions. This move not only boosts Therma Bright’s stake but also positions the company to benefit from potential breakthroughs in asthma and COPD treatments. Leadership and Future Prospects The company’s progress is further supported by recent additions to its advisory board. On August 13, 2024, Therma Bright welcomed Michael Raimondo, a seasoned expert in medical sales and operations, to its advisory board. Raimondo’s extensive experience is expected to drive sales growth and navigate the complexities of U.S. healthcare reimbursement processes. Rob Fia commented on Raimondo’s appointment: "We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the company’s sales efforts of its health-tech and med-tech devices." Conclusion Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) is poised for significant growth following the approval of the HCPCS code for its Venowave VW5 device. This milestone opens up opportunities in the large DVT treatment market. With strategic investments, new partnerships, and technological advancements, TBRIF is well-positioned for future success, potentially making it a compelling stock for investors Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and has been compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

September 09, 2024 06:00 AM Eastern Daylight Time

Syntekabio to Highlight its Cutting-edge AI-driven Discovery Solutions at BioTechX

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its participation at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth. “We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities,” said Jongsun Jung, PhD, CEO of Syntekabio. “We recently announced our ‘Develop Now, Pay Later’ offer that enables clients to test the validity of a target protein of interest without incurring any upfront costs. In addition to identifying potential hits and optimizing small molecule leads, we also have strong capabilities in antibody and cancer neoantigen discovery. We are excited to have the opportunity to highlight these technologies at the conference.” Meet us at BioTechX USA! Syntekabio has several activities planned at the conference. Schedule a meeting by clicking here or stop by our booth (#401) to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges. Don’t miss out on the latest insights in AI presented in our talks! Tuesday, September 17 th 9:20 AM - Keynote presentation Addressing Data Scarcity in D rug Discovery with Physics-based AI Models Jonathan Witztum, PhD, CTO, Syntekabio USA 5:05 PM – AI in drug discovery presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio Recently announced Develop Now, Pay Later offer – drug discovery with no upfront fees Syntekabio’s Develop Now, Pay Later model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher ® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. The client only pays for the work once the agreed upon validated results are obtained. For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here. Additional powerful tools enable novel antibody and cancer neoantigen prediction Additionally, the company will highlight its in silico biologics platforms, Neo-ARS TM and Ab-ARS TM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics. Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process. About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries US & Europe - MC Services AG Laurie Doyle / Dr. Cora Kaiser +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 06, 2024 08:30 AM Eastern Daylight Time

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Benzinga

By Meg Flippin, Benzinga Turning back the clock on aging is a never-ending quest with people, large companies and startups pouring blood, sweat, tears – and tons of money – into finding a solution. One company that seems to be getting closer to its goal is Telomir Pharmaceuticals Inc. (NASDAQ: TELO), a pre-clinical pharma company seeking to lead developments in longevity science through treating age-related conditions. Its leading drug compound, Telomir-1, was featured in an ABC television news segment highlighting promising "age reversal" outcomes in a study with two senior dogs. Lengthening DNA’s Protective Caps Telomir-1, the company's leading drug compound, is designed to regenerate telomeres – the protective DNA structures at the ends of our chromosomes, often compared to the caps on shoelaces. Research has demonstrated that repairing these telomeres may extend biological age and reverse certain age-related conditions. By targeting telomere regeneration, Telomir-1 aims to slow down the aging process and combat diseases linked to telomere shortening. Telomir Pharmaceuticals says Telomir-1 is the first novel small molecule to lengthen the DNA’s protective telomere caps to potentially reverse age-related conditions. The novel molecule, which Telomir is testing with mice and dogs with an eye toward human clinical trials, binds to critical metals that wear down telomeres. By limiting the availability of metals and interrupting the enzyme function, Telomir-1 seeks to restore cellular metal homeostasis and reverse a person's or animal’s biological age. The oral therapy potentially provides what the company says is a safe and effective alternative to existing treatments with minimal side effects. Telomir-1 Gets Props In News Segment In the segment, "ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs," the potential of Telomir-1 was on display through the stories of Zeus and Benson, two senior dogs from Donte's Den rescue organization in Myakka City, Florida. After being treated with Telomir-1, both dogs exhibited improvements in their health conditions, according to Telomir. Zeus, a 12-year-old German Shepherd, showed complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland suffering from severe arthritis, regained his mobility, leading to what caretakers described as a miraculous recovery, reports Telomir. "The results of this study highlight the groundbreaking potential of Telomir-1. Our priority is to advance the rigorous scientific research required to bring this promising treatment to humans and pets through the regulatory process as swiftly and safely as possible," said Erez Aminov, CEO of Telomir. "At Telomir, we are dedicated to transforming the future of longevity science, and these early findings bring us one step closer to making that vision a reality." Aminov was named CEO earlier this month after the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Aminov was most recently CEO of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). The positive preclinical trials have shown that Telomir-1 may have several applications in the veterinary market, which is large given that Americans are poised to spend $156 billion on their pets by the end of this year. The use of Telomir-1 in the two dogs was observed by Telomir's special advisor Dr. Michael Roizen, the former Chief Wellness Officer of the Cleveland Clinic and a leader in age-related medicine. In this small compassionate use program, remarkable improvements in the health and vitality of the dogs after treatment with Telomir-1 were noted, offering a glimpse into the potential future applications for humans, reported Telomir. "The preliminary results we're seeing with Telomir-1 are very encouraging. By lengthening telomeres, we believe Telomir-1 can promote cell regeneration and potentially reverse several aspects of aging or age-related conditions. I'm excited to continue working with Telomir to explore the full potential of this innovative therapy,” Roizen said. More Tests Underway Nobody wants to get old and that includes pets. With Americans pouring tons of money into keeping their pooches happy and healthy, they may someday have another tool: Telmoir-1. With encouraging results out of its study with two dogs and more positive results expected down the road, this may be a company worth paying attention to as the quest to reverse time continues. Featured photo by Simone Dalmeri on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:40 AM Eastern Daylight Time

Image

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Benzinga

By Meg Flippin, Benzinga Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, has inked a collaboration deal with Liquid Biosciences, an AI-focused bio-analytics company, to potentially add pancreatic cancer detection to its colorectal cancer screening test ColoAlert®. Liquid Biosciences leverages its EMERGE AI analysis technology platform to help biopharma companies, diagnostics industries and academic institutions identify effective drugs and therapies. Mainz Biomed is developing PancAlert, a screening test that combines genetic and potentially microbiome biomarkers to detect pancreatic cancer. Research has shown that the microbiome – the mix of bacteria in the gut – plays a big role in how tumors develop and progress. The constitution of the microbiome can potentially hurt the immune system’s ability to recognize and attack cancer and render drugs less effective. By combining DNA and microbiome biomarkers, Mainz is betting early detection of pancreatic cancer is possible. Promising Early Results In the initial phase of the collaboration, the companies evaluated biomarkers from Mainz’s research program, co-funded by the German government, by applying a single algorithm developed by Liquid Biosciences using its EMERGE platform. Mainz said the results of the feasibility analysis were promising, giving both companies confidence that PancAlert could be added to ColoAlert in the future. ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis, offering what the company says is a better early detection than fecal occult blood tests. In the second phase of the collaboration, Mainz and Liquid Biosciences will expand the biomarker evaluation to include microbiome biomarkers Mainz evaluated in 2023 and an expansion of the algorithm. The companies are targeting to complete this analysis in the fourth quarter of 2024. “We are excited by the opportunity to collaborate with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection with the goal of being a first-in-class screening test for this deadly form of cancer,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Liquid Biosciences is already a key partner in our Next Generation colorectal cancer screening test. Expanding our partnership will allow us to bring the power of AI to this critical problem.” Pancreatic Cancer Is Deadly And Growing Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. It is now the third-leading cause of cancer deaths, and by 2030 it is expected to grow to second place, surpassing colorectal cancer deaths. This year alone, about 66,440 Americans will be diagnosed with pancreatic cancer, a record for this deadly form of cancer. What’s more, about 51,750 Americans are expected to die from the disease this year. Among cancers, pancreatic disease is a tough one to treat. It’s a highly aggressive form of cancer that attacks the pancreas, an organ needed for digestion. With limited treatment options, the five-year survival rate is just 13%. It doesn’t help that most people are diagnosed with pancreatic cancer in a late stage when it has already spread to other parts of the body. That’s particularly true with pancreatic ductal adenocarcinoma (PDAC), which is a type of pancreatic cancer that’s created from the cells that line the ducts of the pancreas. It's one of the most lethal forms of pancreatic cancer. Given the difficulty in treating pancreatic cancer and the increasing incidents, a lot of medical research is directed toward earlier detection and better treatments. As a result, the global pancreatic cancer market is projected to reach $7.4 billion by 2032, growing at a CAGR of 13.7% over 2023-2032. Mainz’s collaboration with Liquid Biosciences is the latest in the company’s collaborations to bring its next-generation diagnostics technology to the masses. By combining biomarkers, Mainz is seeking to demonstrate a better and more effective way to spot deadly cancers that currently go undetected and untreated until it's too late. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:35 AM Eastern Daylight Time

Image

September 04, 2024 09:00 AM, Eastern

Benzinga

By Johnny Rice, Benzinga Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer. Cingulate says it will be submitting a New Drug Application within a year. Watch the full interview here: Featured photo by Thought Catalog on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 04, 2024 09:00 AM Eastern Daylight Time

Video Image

1 2 3 4 5 ... 241